Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin oral - Generex Biotechnology

Drug Profile

Insulin oral - Generex Biotechnology

Alternative Names: Insulin buccal - Generex; Oral Recosulin; Oral-lyn; Oral-Lyn-2; Oralgen

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Generex Biotechnology Corporation
  • Developer Generex Biotechnology Corporation; Leosons
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Glucose intolerance

Most Recent Events

  • 04 Jul 2019 Oral insulin is till in under regulatory review for Type 2 diabetes in Jordan, Kuwait, Qatar
  • 04 Jul 2019 Oral insulin is till in under regulatory review for Type 1 diabetes in Jordan, Kuwait, Qatar
  • 23 Mar 2017 Discontinued - Phase-II for Glucose intolerance in Italy (Buccal) (Generex Biotechnology Corporation pipeline, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top